In 2015, the Chinese Society of Hepatology and the Chinese Society of Gastroenterology published a consensus on primary ...

原发性胆汁性胆管炎（primary biliary cholangitis,PBC）是一种慢性自身免疫性肝内胆汁淤积性疾病，多见于中老年女性，早期可无症状，临床常见为乏力和皮肤瘙痒等症状。疾病的早期识别和及时治疗对其预后非常重要。本文介绍了PBC的诊疗要点，以供参考。

Primary sclerosing cholangitis is a disease where the tubes that transfer bile between the liver, gallbladder, and small ...

The global primary biliary cholangitis therapeutics market size was valued at US$732.5 million in 2023 and is projected to reach US$1358.1 billion by 2032, growing at a CAGR of 7.1% from 2024 to 2032.

Primary sclerosing cholangitis (PSC) is a progressive scarring of the liver's bile ducts. According to current estimates, between 5 and 16 in every 100,000 people have PSC. The symptoms of PSC ...

COUR Pharmaceuticals’ emerging platform reprograms the immune system to address the root causes of autoimmune diseases.

Primary sclerosing cholangitis (PSC) is a chronic autoimmune disease with inflammation and stricture formation in the bile ducts inside the liver and/or in the extrahepatic bile duct which drains into ...

Oral vancomycin therapy resulted in clinical response in nearly half of patients with inflammatory bowel disease associated ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...

Results published in the Journal of Crohn's and Colitis revealed that an antibiotic called vancomycin may also be effective in treating people who have a specific type of inflammatory bowel disease ...

(Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis (PBC) in ...